上皮性卵巢癌长期生存未见改善:荷兰1989-2014年人群研究
该研究基于荷兰癌症登记系统,纳入1989至2014年确诊的上皮性卵巢癌(含腹膜和输卵管癌)患者,分析治疗变化与总生存的关系。结果显示,尽管手术分期和化疗强度增加,5年生存率有所提高,但10年生存率在全人群基本不变(24%),提示长期生存未改善。
要点
- 早期患者淋巴结清扫比例从4%升至62%,晚期接受手术加化疗比例从55%升至67%。
- 5年生存率早期从74%升至79%,晚期从16%升至24%,全人群从31%升至34%。
- 10年生存率全人群保持24%不变,分期单独分析改善主要归因于分期迁移。
核心结论
- 尽管治疗和分期程序加强,过去25年上皮性卵巢癌女性的长期生存未改善。
- 5年总生存的改善反映疾病控制延长而非治愈机会增加。
- 早期和晚期分别分析时长期结局的改善主要归因于分期程序改进和分期迁移,合并分析时消失。
研究设计与样本
- 基于荷兰癌症登记系统的基于人群的研究,纳入1989至2014年确诊的上皮性卵巢癌(包括腹膜和输卵管癌)患者。
- 共纳入32,540例患者,其中22,047例(68%)为晚期疾病。
- 使用多变量Cox回归模型分析治疗变化与总生存的关系。
主要发现
- 早期患者中,淋巴结清扫作为手术分期程序的一部分从1989-1993年的4%增至2009-2014年的62%(P < 0.001)。
- 晚期患者中,接受手术和化疗最佳治疗的患者数从1989-1993年的55%增至2009-2014年的67%(P < 0.001)。
- 5年生存率早期从74%升至79%,晚期从16%升至24%,所有患者合计从31%升至34%。
- 10年生存率早期从62%升至67%,晚期从10%升至13%,但所有患者合计保持24%不变。
临床怎么用
- 临床应关注长期生存结局,而不仅限于5年生存率的改善。
- 分期程序改进可能导致分期迁移,解读生存趋势时需考虑合并分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: This study investigates changes in therapy and long-term survival for patients with epithelial ovarian cancer (EOC) in the Netherlands. METHODS: All patients with EOC, including peritoneal and fallopian tube carcinoma, diagnosed in the Netherlands between 1989 and 2014 were selected from the Netherlands Cancer Registry. Changes in therapy were studied and related to overall survival (OS) using multivariable Cox regression models. RESULTS: A total of 32,540 patients were diagnosed with EOC of whom 22,047 (68%) had advanced stage disease. In early stage, lymph node dissection as part of surgical staging procedures increased over time from 4% in 1989-1993 to 62% in 2009-2014 (P < 0.001). In advanced stage, the number of patients receiving optimal treatment with surgery and chemotherapy increased from 55% in 1989-1993 to 67% in 2009-2014 (P < 0.001). Five-year survival rates improved in both early stage (74% versus 79%) and advanced stage (16% versus 24%) as well as in all patients combined (31% versus 34%). Ten-year survival rates, however, slightly improved in early stage (62% versus 67%) and advanced stage (10% versus 13%) but remained essentially unchanged at 24% for all patients combined. CONCLUSION: Despite intensified treatment and staging procedures, long-term survival for women with EOC has not improved in the last 25 years. The observed improvements in 5-year OS reflect a more prolonged disease control rather than better chances for cure. Furthermore, the apparent better long-term outcome, when early and advanced stage patients are analysed separately, is largely due to improved staging procedures and the ensuing stage migration. These effects disappear in a combined analysis of all patients.
引用
- Timmermans M, Sonke GS, Van de Vijver KK, et al. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2017. PMID: 29179135. doi:10.1016/j.ejca.2017.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。